| 2026-08-12 | Press release | Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers |
| 2026-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Transcript | Q4 FY23 earnings call transcript |
| 2026-08-06 | Press release | Natera Reports Second Quarter 2026 Financial Results |
| 2026-08-06 | Deck | Natera, Inc. Q2 Earnings Conference Call · 2026 |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-05 | Press release | Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer |
| 2026-07-30 | Press release | Natera to Report its Second Quarter Results on August 6, 2026 |
| 2026-07-22 | Press release | Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study |
| 2026-07-16 | Press release | Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio |
| 2026-07-09 | Press release | Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers |
| 2026-07-06 | Press release | Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer |
| 2026-07-06 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-29 | Press release | Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Hea |
| 2026-06-25 | Press release | Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial |
| 2026-06-24 | Press release | Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer |
| 2026-06-23 | Press release | NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update |
| 2026-06-18 | Press release | Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress |
| 2026-06-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-16 | 8-K | Form 8-K/A, Item 5.02 |
| 2026-06-05 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-04 | Press release | Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis |
| 2026-06-03 | Press release | Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors |
| 2026-05-29 | Press release | Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma |
| 2026-05-28 | Press release | Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Bre |
| 2026-05-26 | Press release | Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology |
| 2026-05-21 | Press release | Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology |
| 2026-05-21 | Press release | Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World |
| 2026-05-20 | Press release | EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled |
| 2026-05-15 | Press release | Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Deck | Natera, Inc. Q1’2026 Earnings Presentation |
| 2026-05-07 | Press release | Natera to Report its First Quarter Results on May 7, 2026 |
| 2026-05-07 | Press release | Natera Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | Supplement | Reconciliation of Non-GAAP cash flow · Q1 2026 |
| 2026-04-30 | Press release | Natera to Report its First Quarter Results on May 7, 2026 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-22 | Press release | Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT |